Cambridge researchers awarded Advanced Grants from the European Research Council
The successful Cambridge grantees’ work covers a range of research areas, including the development of next-generation semiconductors, new methods to identify dyslexia in young children, how diseases spread between humans and animals, and the early changes that happen in cells before breast cancer develops, with the goal of finding ways to stop the disease before it starts.
The funding, worth €721 million in total, will go to 281 leading researchers across Europe. The Advanced Grant competition is one of the most prestigious and competitive funding schemes in the EU and associated countries, including the UK. It gives senior researchers the opportunity to pursue ambitious, curiosity-driven projects that could lead to major scientific breakthroughs. Advanced Grants may be awarded up to € 2.5 million for a period of five years. The grants are part of the EU’s Horizon Europe programme. The UK agreed a deal to associate to Horizon Europe in September 2023.
This competition attracted 2,534 proposals, which were reviewed by panels of internationally renowned researchers. Over 11% of proposals were selected for funding. Estimates show that the grants will create approximately 2,700 jobs in the teams of new grantees. The new grantees will be based at universities and research centres in 23 EU Member States and associated countries, notably in the UK (56 grants), Germany (35), Italy (25), the Netherlands (24), and France (23).
“Many congratulations to our Cambridge colleagues on these prestigious ERC funding awards,” said Professor Sir John Aston, Cambridge’s Pro-Vice-Chancellor for Research. “This type of long-term funding is invaluable, allowing senior researchers the time and space to develop potential solutions for some of biggest challenges we face. We are so fortunate at Cambridge to have so many world-leading researchers across a range of disciplines, and I look forward to seeing the outcomes of their work.”
The Cambridge recipients of 2025 Advanced Grants are:
Professor Clare Bryant (Department of Veterinary Medicine) for investigating human and avian pattern recognition receptor activation of cell death pathways, and the impact on the host inflammatory response to zoonotic infections.
Professor Sir Richard Friend (Cavendish Laboratory/St John’s College) for bright high-spin molecular semiconductors.
Professor Usha Goswami (Department of Psychology/St John’s College) for a cross-language approach to the early identification of dyslexia and developmental language disorder using speech production measures with children.
Professor Regina Grafe (Faculty of History) for colonial credit and financial diversity in the Global South: Spanish America 1600-1820.
Professor Judy Hirst (MRC Mitochondrial Biology Unit/Corpus Christi College) for the energy-converting mechanism of a modular biomachine: Uniting structure and function to establish the engineering principles of respiratory complex I.
Professor Matthew Juniper (Department of Engineering/Trinity College) for adjoint-accelerated inference and optimisation methods.
Professor Walid Khaled (Department of Pharmacology/Magdalene College) for understanding precancerous changes in breast cancer for the development of therapeutic interceptions.
Professor Adrian Liston (Department of Pathology/St Catharine’s College) for dissecting the code for regulatory T cell entry into the tissues and differentiation into tissue-resident cells.
Professor Róisín Owens (Department of Chemical Engineering and Biotechnology/Newnham College) for conformal organic devices for electronic brain-gut readout and characterisation.
Professor Emma Rawlins (Department of Physiology, Development and Neuroscience/Gurdon Institute) for reprogramming lung epithelial cell lineages for regeneration.
Dr Marta Zlatic (Department of Zoology/Trinity College) for discovering the circuit and molecular basis of inter-strain and inter-species differences in learning
“These ERC grants are our commitment to making Europe the world’s hub for excellent research,” said Ekaterina Zaharieva, European Commissioner for Startups, Research, and Innovation. “By supporting projects that have the potential to redefine whole fields, we are not just investing in science but in the future prosperity and resilience of our continent. In the next competition rounds, scientists moving to Europe will receive even greater support in setting up their labs and research teams here. This is part of our “Choose Europe for Science” initiative, designed to attract and retain the world’s top scientists.”
“Much of this pioneering research will contribute to solving some of the most pressing challenges we face - social, economic and environmental,” said Professor Maria Leptin, President of the European Research Council. “Yet again, many scientists - around 260 - with ground-breaking ideas were rated as excellent, but remained unfunded due to a lack of funds at the ERC. We hope that more funding will be available in the future to support even more creative researchers in pursuing their scientific curiosity.”
Eleven senior researchers at the University of Cambridge have been awarded Advanced Grants from the European Research Council – the highest number of grants awarded to any institution in this latest funding round.
Westend61 via Getty ImagesScientist pipetting samples into eppendorf tube
The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.
Evolution made us cheats, now free-riders run the world and we need to change, new book warns
In Invisible Rivals, published by Yale University Press today, Dr Goodman argues that throughout human history we have tried to rid our social groups of free-riders, people who take from others without giving anything back. But instead of eliminating free-riders, human evolution has just made them better at hiding their deception.
Goodman explains that humans have evolved to use language to disguise selfish acts and exploit our cooperative systems. He links this ‘invisible rivalry’ to the collapse of trust and consequent success of political strongmen today.
Goodman says: “We see this happening today, as evidenced by the rise of the Julius Caesar of our time—Donald Trump— but it is a situation that evolution has predicted since the origins of life and later, language, and which will only change form again even if the current crises are overcome.”
Goodman argues that over the course of human evolution “When we rid ourselves of ancient, dominant alphas, we traded overt selfishness for something perhaps even darker: the ability to move through society while planning and coordinating.”
“As much as we evolved to use language effectively to work together, to overthrow those brutish and nasty dominants that pervaded ancient society, we also (and do) use language to create opportunities that benefit us … We use language to keep our plans invisible. Humans, more than other known organisms, can cooperate until we imagine a way to compete, exploit, or coerce, and almost always rely on language to do so.”
Goodman, an expert on human social evolution at the University of Cambridge, identifies free-riding behaviour in everything from benefits cheating and tax evasion, to countries dodging action on climate change, and the actions of business leaders and politicians.
Goodman warns that “We can’t stop people free-riding, it’s part of our nature, the incurable syndrome… Free riders are among us at every level of society and pretending otherwise can make our own goals unrealistic, and worse, appear hopeless. But if we accept that we all have this ancient flaw, this ability to deceive ourselves and others, we can design policies around that and change our societies for the better.”
Lessons from our ancestorsGoodman points out that humans evolved in small groups meaning that over many generations we managed to design social norms to govern the distribution of food, water and other vital resources.
“People vied for power but these social norms helped to maintain a trend toward equality, balancing out our more selfish dispositions. Nevertheless, the free-rider problem persisted and using language we got better at hiding our cheating.”
One academic camp has argued that ancient humans used language to work together to overthrow and eject “brutish dominants”. The opposing view claims that this never happened and that humans are inherently selfish and tribal. Goodman rejects both extremes.
“If we accept the view that humans are fundamentally cooperative, we risk trusting blindly. If we believe everyone is selfish, we won’t trust anyone. We need to be realistic about human nature. We’re a bit of both so we need to learn how to place our trust discerningly.”
Goodman points out that our distant ancestors benefitted from risk-pooling systems, whereby all group members contributed labour and shared resources, but this only worked because it is difficult to hide tangible assets such as tools and food. While some hunter-gatherer societies continue to rely on these systems, they are ineffective in most modern societies in our globalized economy.
“Today most of us rely largely on intangible assets for monetary exchange so people can easily hide resources, misrepresent their means and invalidate the effectiveness of social norms around risk pooling,” Goodman says.
“We are flawed animals capable of deception, cruelty, and selfishness. The truth is hard to live with but confronting it through honest reflection about our evolutionary past gives us the tools to teach ourselves and others about how we can improve the future.”
Taking action: self-knowledge, education & policyGoodman, who teaches students at Cambridge about the evolution of cooperation, argues that we reward liars from a young age and that this reinforces bad behaviour into adulthood.
“People tell children that cheaters don’t prosper, but in fact cheats who don’t get caught can do very well for themselves.”
“Evolutionarily speaking, appearing trustworthy but being selfish can be more beneficial to the individual. We need to recognise that and make a moral choice about whether we try to use people or to work with them.”
At the same time, Goodman thinks we need to arm ourselves intellectually with the power to tell who is credible and who is not. “Our most important tool for doing this is education,” he says. “We must teach people to think ethically for themselves, and to give them the tools to do so.”
But Goodman cautions that even the tools we use to expose exploiters are open to exploitation: “Think about how people across the political sphere accuse others of virtue signalling or abusing a well-intentioned political movement for their own gain.”
Goodman believes that exposing free-riders is more beneficial than punishment. “Loss of social capital through reputation is an important motivator for anyone,” he argues, suggesting that journalistic work exposing exploitation can be as effective at driving behaviour change as criminal punishment.
“The dilemma each of us faces now is whether to confront invisible rivalry or to let exploiters undermine society until democracy in the free world unravels—and the freedom of dissent is gone.”
Dr Jonathan R Goodman is a research associate at Cambridge Public Health and a social scientist at the Wellcome Sanger Institute.
Invisible Rivals: How We Evolved to Compete in a Cooperative World is published by Yale University Press on 17 June 2025 (ISBN: 9780300274356)
To save democracy and solve the world's biggest challenges, we need to get better at spotting and exposing people who exploit human cooperation for personal gain, argues Cambridge social scientist Dr Jonathan Goodman.
If we accept that we all have this ancient flaw, we can change our societies for the betterJonathan R GoodmanRalph via PixabayClose up of a handshake between two men wearing suits, with dollar bills in the background
The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.
Cambridge PhD student heading to CERN for the International FameLab final
After winning a nail-biting East of England final, which was held as part of the Cambridge Festival in April 2025, Spatika went on to represent the East of England in the UK final with her presentation on Time Travel with Your Brain. She will now go on to represent the UK in the International Final taking place live at CERN Science Gateway in Switzerland to mark the 20 year anniversary of the competition.
“I was so surprised I won!”, said Spatika. “The other communicators were fantastic and we travelled through so many topics from planets to parasites and more!”.
Spatika took part in FameLab because she enjoyed talking about science to non-scientists and bringing some meaning to the complex work taking place in the labs. “I wanted a chance to bring humour into the science, because most of the times science is presented in professional environments, it’s all very serious”, added Spatika.
“I would recommend FameLab for anyone who’s even a tiny bit interested in knowing what happens to science when it’s let out in the wild!”
Claudia Antolini, Public Engagement Manager at the University of Cambridge said, “We are delighted for Spatika to represent the UK at the International FameLab final. Both at the East of England regional competition and the UK final Spatika gave outstanding performances, scientifically accurate but also extremely engaging with wise-cracking humour. We wish her the best of luck and we look forward to cheering her on for the International Final.”
The FameLab final will be streamed live from CERN on YouTube.
Spatika Jayaram is a PhD student and Gates Cambridge Scholar in the Department of Physiology, Development and Neuroscience and Magdalene College. In her research, she looks at social and emotional behaviours emerging across development, and how regions within the prefrontal cortex contribute to their regulation.
FameLab was created by Cheltenham Festivals in 2005 and is the largest science communication competition and training programme in the world. Participants have just three minutes to convey a scientific concept of their choice to an audience and expert panel of judges with no presentations and limited props.
Earlier this month, Cambridge PhD student Spatika Jayaram was crowned the winner of the FameLab 2025 UK final at this year’s Cheltenham Science Festival.
Still Moving Media for Cheltenham Festivals
The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.
Pilkington Prizes awarded to teaching staff
This year's prize winners are;
Dr Tore Butlin - Department of Engineering/Queens' College
Tore has played a key role in reshaping the engineering course content and led the design of the new IA mechanics syllabus.
Dr Alexander Carter - Institute of Continuing Education/Fitzwilliam College
As Academic Director for Philosophy & Interdisciplinary Studies, Alexander leads a broad-ranging portfolio of undergraduate and postgraduate courses in philosophy, creativity theory and research skills.
Dr Nicholas Evans - Department of Clinical Neurosciences/Wolfson College
Nicholas has demonstrated an impressive commitment to medical education at the Clinical School for over a decade. As a mentor he has also shown a keen interest in student welfare.
Dr James Fergusson - Department of Applied Mathematics and Theoretical Physics
James is an outstanding lecturer who brings outstanding passion to everything he does. He has been heavily involved in establishing and supporting the new MPhil in Data Intensive science.
Dr Marta Halina - Department of History and Philosophy of Science/Selwyn College
Marta has almost single-handedly overhauled the History and Philosophy of Science Tripos making it a more sought after course. She has led a major restructuring of the MPhil course and has introduced the increasingly popular module, AI in healthcare.
Paul Hoegger - University Language Centre/Faculty of Modern and Medieval Languages and Linguistics/Fitzwilliam College
Paul is a teacher of German much respected by generations of students. Over the years he has created several new courses including one on German literature through the ages and one on the poetry of Schubert.
Dr Kate Hughes - Department of Veterinary Medicine/Girton College
Kate makes a valued contribution to Years 4 - 6 of the veterinary programme. She led the design of a new final year rotation in anatomic pathology for which she is educational lead.
Dr Mairi Kilkenny - Department of Biochemistry/Queen's College
Mairi delivers innovative and creative teaching with the Department of Biochemistry often incorporating digital media to stimulate the interest of her students. She's also a supervisor for several Colleges.
Dr Ewa Marek - Department of Chemical Engineering and Biotechnology/Jesus College
Ewa is a valued lecturer, supervisor and Director of Studies. Passionate about sustainability, Ewa developed a new Part 1A course which introduces the topic in the context of chemical and biochemical engineering.
Dr Isabelle McNeill - Faculty of Modern and Medieval Languages and Linguistics/Trinity Hall
Isabelle was a passionate and outstanding teacher who made vibrant contributions to French and to Film and Screen within the Faculty. A co-founder and trustee of the Cambridge Film Trust, Isabelle was made aware of her prize two days before she sadly passed away in February. She will be much missed by colleagues and students alike.
Dr Ali Meghji - Department of Sociology/Sidney Sussex College
Ali has been instrumental in creating a whole new Tripos paper in the Department (Empire, Colonialism, Imperialism). As a teacher, he repeatedly receives glowing comments from students on the clarity of his exposition, the contemporary relevance of his topics, and his effective use of technology.
Dr Liam Saddington - Department of Geography/Lucy Cavendish College
Liam was recruited as Training and Skills Director for the Tripos with a remit to oversee the quantitative and qualitative research training across the degree. He has led new innovations, such as creating a museum field trip for first-year students, organising a 'COP Cambridge' simulation for second-year students, and developing the dissertation 'research carousel'.
Dr Christopher Tilmouth - Faculty of English
Chris' visionary leadership has reshaped both undergraduate and postgraduate education at Cambridge. As Director of Undergraduate Studies, Chris introduced critical reforms to enhance student progression.
Dr Juliet Usher-Smith - Department of Public Health and Primary Care/Emmanuel College
Juliet has made important contributions to the Department through direct teaching, supervision and mentoring and goes the extra mile to foster a culture in which teaching and learning is valued by all.
The winners were presented with their awards by the University's Vice-Chancellor, Professor Deborah Prentice, at a ceremony also attended by Senior Pro-Vice-Chancellor (Education and Environmental Sustainability), Professor Bhaskar Vira. He said “The Pilkington Prize Award ceremony is one of my favourite events in the University calendar. It’s always deeply satisfying to see hard-working staff recognised for their commitment and dedication to teaching and learning. We all know that behind every great student is a great teacher and I feel privileged to work alongside such excellent colleagues.”
A total of fourteen dedicated and talented staff have been awarded the Pilkington Prize this year. The annual prizes are awarded in the name of Sir Alastair Pilkington to acknowledge excellence in teaching and to recognise the contribution each individual makes to a Department or Faculty.
It’s always deeply satisfying to see hard-working staff recognised for their commitment and dedication to teaching and learningProf Bhaskar ViraLloyd Mann Winners of the 2025 Pilkington Prize
The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.
Cambridge University academics recognised in King’s Birthday Honours 2025
Cambridge Zero Director Professor Emily Shuckburgh (Fellow of Darwin, Trinity alumna) has received a CBE for services to Climate Science and to the Public Communication of Climate Science.
"I am deeply honoured to accept this recognition, which is a reflection of the collective efforts of many scientists, communicators, educators, and advocates who strive every day to make climate science accurate, accessible and actionable at a time when honesty, clarity and urgency are more important than ever,” Professor Shuckburgh said.
Alongside leading the University of Cambridge’s major climate change initiative, Cambridge Zero, Emily is also Professor of Environmental Data Science at the Department of Computer Science and Technology. Her primary research is focused on the application of AI to climate science and in this context she is Academic Director of the Institute of Computing for Climate Science, and co-Director of the UKRI Centre for Doctoral Training on the Application of AI to the study of Environmental Risks (AI4ER).
Professor Gordon Dougan (Fellow of Wolfson College), an Emeritus Professor who continues to work in the University’s Department of Medicine, and former Director of the Infection Health Challenge area at Wellcome, UK, has been awarded a CBE For services to Vaccines and to Global Health.
Prof Dougan is an internationally recognised expert in vaccinology, global health and infections. He was Head of Pathogens at The Wellcome Sanger Institute (WTSI) for over a decade and worked in the pharmaceutical industry (Wellcome Foundation/GSK) for part of his career, developing novel vaccines and other medicines. He has worked as an advisor to health agencies, industry, academia and regulatory agencies. He is an expert on the molecular basis of infection with a strong emphasis on pathogenic mechanisms/immunity, genomics, disease tracking and antibiotic resistance. He is currently President of the Microbiology Society of the UK.
He said: “I am delighted to receive this important recognition for my work and the people I have worked with and for. Applying science to the benefit of people and health is what I have been working toward throughout my career. I can recommend this path to anyone.”
Details of University alumni who are recognised in the King's Birthday Honours will be published on www.alumni.cam.ac.uk.
The University extends its congratulations to all academics, staff and alumni who have received an honour.
Academics at the University of Cambridge are among those featured in the King's Birthday Honours 2025, which recognises the achievements and contributions of people across the UK.
The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.
How ‘supergenes’ help fish evolve into new species
Why are there so many different kinds of animals and plants on Earth? One of biology’s big questions is how new species arise and how nature’s incredible diversity came to be.
Cichlid fish from Lake Malawi in East Africa offer a clue. In this single lake, over 800 different species have evolved from a common ancestor in a fraction of the time it took for humans and chimpanzees to evolve from their common ancestor.
What’s even more remarkable is that the diversification of cichlids happened all in the same body of water. Some of these fish became large predators, others adapted to eat algae, sift through sand, or feed on plankton. Each species found its own ecological niche.
Now, researchers from the Universities of Cambridge and Antwerp have determined how this evolution may have happened so quickly. Their results are reported in the journal Science.
The researchers looked at the DNA of over 1,300 cichlids to see if there’s something special about their genes that might explain this rapid evolution. “We discovered that, in some species, large chunks of DNA on five chromosomes are flipped – a type of mutation called a chromosomal inversion,” said senior author Hennes Svardal from the University of Antwerp.
Normally, when animals reproduce, their DNA gets reshuffled in a process called recombination – mixing the genetic material from both parents. But this mixing is blocked within a chromosomal inversion. This means that gene combinations within the inversion are passed down intact without mixing, generation after generation, keeping useful adaptations together and speeding up evolution.
“It’s sort of like a toolbox where all the most useful tools are stuck together, preserving winning genetic combinations that help fish adapt to different environments,” said first author Moritz Blumer from Cambridge’s Department of Genetics.
These preserved sets of genes are sometimes called ‘supergenes. In Malawi cichlids, the supergenes seem to play several important roles. Although cichlid species can still interbreed, the inversions help keep species separate by preventing their genes from blending too much. This is especially useful in parts of the lake where fish live side by side – like in open sandy areas where there’s no physical separation between habitats.
The genes inside these supergenes often control traits that are key for survival and reproduction – such as vision, hearing, and behaviour. For example, fish living deep in the lake (down to 200 meters) need different visual abilities than those near the surface, require different food, and need to survive at higher pressures. Their supergenes help maintain those special adaptations.
“When different cichlid species interbred, entire inversions can be passed between them – bringing along key survival traits, like adaptations to specific environments, speeding up the process of evolution,” said Blumer.
The inversions also frequently act as sex chromosomes, helping determine whether a fish becomes male or female. Since sex chromosomes can influence how new species form, this opens new questions about how evolution works.
“While our study focused on cichlids, chromosomal inversions aren’t unique to them,” said co-senior author Professor Richard Durbin, from Cambridge’s Department of Genetics. “They’re also found in many other animals — including humans — and are increasingly seen as a key factor in evolution and biodiversity.”
“We have been studying the process of speciation for a long time,” said Svardal. “Now, by understanding how these supergenes evolve and spread, we’re getting closer to answering one of science’s big questions: how life on Earth becomes so rich and varied.”
Reference:
L. M. Blumer, V. Burskaia, I. Artiushin, J. Saha et al. ‘Introgression dynamics of sex- linked chromosomal inversions shape the Malawi cichlid radiation.’ Science (2025). DOI: 10.1126/science.adr9961
Researchers have found that chunks of ‘flipped’ DNA can help fish quickly adapt to new habitats and evolve into new species, acting as evolutionary ‘superchargers’.
banusevim via Getty ImagesDolphin cichlid (Cyrtocara moorii)
The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.
Cambridge scholar helps bring Ukraine’s pain and power to the stage in critically acclaimed creative collaboration
The Guardian calls it “shattering.” The Stage heralds it as a “challenging, artfully constructed indictment of Russian war crimes in Ukraine.”
Written by Anastasiia Kosodii and Josephine Burton, and directed by Burton, The Reckoning channels voices of Ukrainians across the country – a priest, a volunteer, a dentist, a security guard, a journalist – who are forced to confront the sudden horrors of invasion and occupation and to repair bonds of trust amid violence and fear. These voices are real, drawn from witness statements collected and conserved by the journalists and lawyers behind The Reckoning Project.
Rory Finnin, Professor of Ukrainian Studies and a Fellow of Robinson College at Cambridge, collaborated with Burton to help shape the play. His decades of research into Ukraine’s culture and society formed the basis for a grant in support of The Reckoning from the University of Cambridge’s AHRC Impact Starter Fund account.
“Our collaboration with Rory Finnin has been invaluable throughout the making of The Reckoning,” said Burton, who is also Artistic Director and Chief Executive of Dash Arts. “Rory’s insights into Ukraine’s past and present gave me deeper grounding as a director and co-writer and helped sharpen the questions the play asks of its audience.”
The Reckoning blends dynamic storytelling with movement, music, and food to forge new routes of solidarity and understanding with the audience. As Everything Theatre notes in a glowing review, “We leave not as passive spectators but as an active part of the struggle.”
Attendees share in a summer salad made over the course of the play by the Ukrainian and British cast – Tom Godwin, Simeon Kyslyi, Marianne Oldham, and Olga Safronova – who bring empathy, humour, and integrity to each scene. The conclusion of each performance features an invited speaker from the audience who comes to the stage to reckon with their own experience of the play from different ethical and intellectual perspectives.
Professor Finnin spoke on the play’s first night at the Arcola Theatre.
“Over three years into Russia’s full-scale invasion, we are too often tempted to turn our eyes away from Ukraine,” said Finnin. “But The Reckoning empowers us to look closely and to see with new purpose. It has been an incredible privilege to support a dynamic work of art that brings Ukrainian voices to the fore and challenges us to listen and respond to them, with urgency and moral clarity.”
The Reckoning runs through 28 June at London’s Arcola Theatre.
The Reckoning is an intimate work of documentary theatre composed from a verified archive of witness testimonies chronicling Russia’s war of aggression. It is now playing at London’s Arcola Theatre to universal acclaim.
We are too often tempted to turn our eyes away from UkraineRory FinninDash ArtsThe Reckoning being performed at the Arcola Theatre, London, in 2025
The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.
Menstrual tracking app data is a ‘gold mine’ for advertisers that risks women’s safety – report
Smartphone apps that track menstrual cycles are a “gold mine” for consumer profiling, collecting information on everything from exercise, diet and medication to sexual preferences, hormone levels and contraception use.
This is according to a new report from the University of Cambridge’s Minderoo Centre for Technology and Democracy, which argues that the financial worth of this data is “vastly underestimated” by users who supply profit-driven companies with highly intimate details in a market lacking in regulation.
The report’s authors caution that cycle tracking app (CTA) data in the wrong hands could result in risks to job prospects, workplace monitoring, health insurance discrimination and cyberstalking – and limit access to abortion.
They call for better governance of the booming ‘femtech’ industry to protect users when their data is sold at scale, arguing that apps must provide clear consent options rather than all-or-nothing data collection, and urge public health bodies to launch alternatives to commercial CTAs.
“Menstrual cycle tracking apps are presented as empowering women and addressing the gender health gap,” said Dr Stefanie Felsberger, lead author of the report from Cambridge’s Minderoo Centre. “Yet the business model behind their services rests on commercial use, selling user data and insights to third parties for profit.”
“There are real and frightening privacy and safety risks to women as a result of the commodification of the data collected by cycle tracking app companies.”
As most cycle tracking apps are targeted at women aiming to get pregnant, the download data alone is of huge commercial value, say researchers, as – other than home buying – no life event is linked to such dramatic shifts in consumer behaviour.
In fact, data on pregnancy is believed to be over two hundred times more valuable than data on age, gender or location for targeted advertising. The report points out that period tracking could also be used to target women at different points in their cycle. For example, the oestrogen or ‘mating’ phase could see an increase in cosmetics adverts.
Just the three most popular apps had estimated global download figures of a quarter of a billion in 2024. So-called femtech – digital products focused on women’s health and wellbeing – is estimated to reach over US$60 billion by 2027, with cycle tracking apps making up half of this market.
With such intense demand for period tracking, the report argues that the UK’s National Health Service (NHS) should develop its own transparent and trustworthy app to rival those from private companies, with apps allowing permission for data to be used in valid medical research.
“The UK is ideally positioned to solve the question of access to menstrual data for researchers, as well as privacy and data commodification concerns, by developing an NHS app to track menstrual cycles,” said Felsberger, who points out that Planned Parenthood in the US already has its own app, but the UK lacks an equivalent.
“Apps that are situated within public healthcare systems, and not driven primarily by profit, will mitigate privacy violations, provide much-needed data on reproductive health, and give people more agency over how their menstrual data is used.”
“The use of cycle tracking apps is at an all-time high,” said Prof Gina Neff, Executive Director of Cambridge’s Minderoo Centre. “Women deserve better than to have their menstrual tracking data treated as consumer data, but there is a different possible future.”
“Researchers could use this data to help answer questions about women’s health. Care providers could use this data for important information about their patients’ health. Women could get meaningful insights that they are searching for,” Neff said.
In the UK and EU, period tracking data is considered “special category”, as with that on genetics or ethnicity, and has more legal safeguarding. However, the report highlights how in the UK, apps designed for women's health have been used to charge women for illegally accessing abortion services
In the US, data about menstrual cycles has been collected by officials in an attempt to undermine abortion access. Despite this, data from CTAs are regulated simply as “general wellness” and granted no special protections.
“Menstrual tracking data is being used to control people’s reproductive lives,” said Felsberger. “It should not be left in the hands of private companies.”
Investigations by media, non-profit, and consumer groups have revealed CTAs sharing data with third parties ranging from advertisers and data brokers to tech giants such as Facebook and Google.
The report cites work published last month from Privacy International showing that, while the major CTA companies have updated their approach to data sharing, device information is still collected in the UK and US with “no meaningful consent”.
Despite data protection improvements, the report suggests that user information is still shared with third parties such as cloud-based delivery networks that move the data around, and outside developers contracted to handle app functionalities.
At the very least, commercial apps could include delete buttons, says Felsberger, allowing users to erase data in the app as well as the company servers, helping protect against situations – from legal to medical – where data could be used against them.
“Menstrual tracking in the US should be classed as medical data,” said Felsberger. “In the UK and EU, where this data is already afforded special category status, more focus needs to be placed on enforcing existing regulation.”
The report stresses the need to improve public awareness and digital literacy around period tracking. The researchers argue that schools should educate students on medical data apps and privacy, so young people are less vulnerable to health hoaxes.
The report ‘The High Stakes of Tracking Menstruation’ is authored by Dr Stefanie Felsberger with a foreword by Professor Gina Neff and published by the Minderoo Centre for Technology and Democracy (MCTD).
Cambridge researchers urge public health bodies like the NHS to provide trustworthy, research-driven alternatives to platforms driven by profit.
Women deserve better than to have their menstrual tracking data treated as consumer dataProf Gina NeffEKIN KIZILKAYA via GettyMenstruation cycle application on smart phone
The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.
Cambridge to offer cutting-edge ultrasound treatment for NHS cancer patients in UK first
The Edison Histotripsy System was purchased thanks to a generous donation to the University of Cambridge from Hong Kong-based philanthropist Sir Ka-shing Li, a longstanding supporter of cancer research at the University.
Histotripsy uses pulsed sound waves to create ‘bubble clouds’ from gases present in targeted tissue. These bubble clouds form and collapse in microseconds, creating mechanical forces able to destroy tissue at cellular and sub-cellular levels while avoiding ionising energy of radiation, heat damage from thermal treatments, or the need for surgery.
Treatment is delivered via a single short session – potentially taking no longer than 30 minutes – with limited or no pain, a quick recovery, and can be performed as a day case. The speed of delivery has the potential to reduce cancer treatment times, avoid disease progression and improve cancer survival.
The system will be demonstrated today by Dr Teik Choon See, Consultant Interventional Radiologist at Cambridge University Hospitals NHS Foundation Trust (CUH). Guests will include Solina Chau, Director of the Li Ka Shing Foundation, and Baroness Merron, Parliamentary Under-Secretary of State at the Department of Health and Social Care (DHSC).
The machine, manufactured by HistoSonics, is expected to be fully installed at CUH later this year, where it will be used initially to treat patients with primary and secondary liver tumours before being expanded to treat tumours in other organs.
Previously, 23 patients from Europe were recruited in a histotripsy clinical trial that was completed in 2022. So far, over 1,500 patients worldwide have received treatment using histotripsy, mainly in the United States following approval by the US Food and Drug Administration in late 2023. The machine at Cambridge will be the first in the UK and Europe to treat patients as part of their clinical care pathway, outside the trial setting
Professor Deborah Prentice, Vice-Chancellor of the University of Cambridge, said: “Through his longstanding support of cancer research at Cambridge, Sir Ka-shing Li continues to make a significant impact on outcomes for cancer patients. Cutting-edge technology such as this histotripsy machine allows Cambridge to remain at the forefront of understanding and treating cancer, a position we aim to strengthen further with Cambridge Cancer Research Hospital.”
Roland Sinker, Chief Executive of CUH said: “Histotripsy is an exciting new technology that will make a huge difference to patients. By offering this non-invasive, more targeted treatment we can care for more people as outpatients and free up time for surgeons to treat more complex cases. The faster recovery times mean patients will be able to return to their normal lives more quickly, which will also reduce pressure on hospital beds, helping us ensure that patients are able to receive the right treatment at the right time. We are delighted to be receiving this new state of the art machine.”
Fiona, who has lived with cancer for over two decades, is Co-Chair of the Patient Advisory Group for Cambridge Cancer Research Hospital, and has been involved in planning and designing the new hospital, said: “This is seriously good news. A new, non-invasive option to treat these cancers is very welcome indeed. For patients for whom ordinary surgery is no longer an option, this could make all the difference.”
Health and Social Care Secretary Wes Streeting granted authorisation for controlled early access to the device via an unmet clinical need authorisation. Available through the UK’s Innovative Devices Access Pathway programme, this bypasses red tape to accelerate lengthy authorisation stages, so NHS patients benefit from it years earlier than planned.
Wes Streeting said: “Bureaucracy has become a handbrake on ambition, stopping innovation in its tracks and holding our health service back. But through our Plan for Change, we are slashing red tape, so game-changing new treatments reach the NHS front line quicker – transforming healthcare.
“Regulation is vital to protect patients. However, as the pace of innovation ramps up, our processes must be more agile to help speed the shift from analogue to digital. Our common-sense approach to regulation will streamline approval processes so countless more patients are liberated from life-limiting conditions.”
Last year, an £11million donation was made in honour of Sir Ka-shing Li to support the now-renamed Li Ka Shing Early Cancer Institute. Sir Ka-shing Li has previously made generous donations to support cancer research at the University, including in 2007 to the Li Ka Shing Centre, which houses the CRUK Cambridge Institute.
Cutting-edge technology such as the histotripsy machine will enable Cambridge Cancer Research Hospital, a partnership with Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, to change the story of cancer. The University and Addenbrooke's Charitable Trust (ACT) are fundraising for the new hospital, which will transform how we diagnose and treat cancer. The hospital will treat patients across the East of England, but the research that takes place there promises to change the lives of cancer patients across the UK and beyond. Find out more here.
NHS patients at Addenbrooke’s Hospital, Cambridge, will become the first in the UK and Europe to undergo incisionless ultrasound surgery using a cutting-edge ‘histotripsy machine’ as part of their cancer care.
Through his longstanding support of cancer research at Cambridge, Sir Ka-shing Li continues to make a significant impact on outcomes for cancer patientsDeborah Prentice, Vice-ChancellorHistoSonicsStock image of the Edison histotripsy system
The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.
Cambridge and DSIT announce prestigious Spärck AI Scholarships to support next generation of AI leaders
The scholarships, aimed at exceptionally high-potential domestic and international students, will support study towards AI-related Master’s degrees and provide an unparalleled package of benefits. Students will receive full tuition fees, a living stipend, and access to priority work placements with leading UK AI companies and government institutions.
The programme, which will open to its first cohort in the 2026/27 academic year, intends to enrol 100 scholars over its first four years. Scholars will be selected from the top 1% of AI talent worldwide, with applicants required to demonstrate academic excellence, leadership, and ambassadorial potential, alongside a STEM background.
Uniquely, the Spärck AI Scholarships will provide its students with priority access to work placements within UK-based AI companies and organisations, including the UK government’s AI Security Institute (AISI) and i.AI, their in-house AI incubator.
The scholarships are named in honour of Professor Karen Spärck Jones (1935–2007), a pioneering British computer scientist whose ground breaking work at Cambridge University laid the foundations for modern search engines and natural language processing. One of the most remarkable women in computer science, her seminal 1972 paper introduced the concept of inverse document frequency (IDF), a fundamental principle still central to information retrieval today.
karen_sparck.jpgProfessor Deborah Prentice, University of Cambridge Vice-Chancellor, said: “Cambridge combines academic excellence with a dynamic, interdisciplinary AI community, from foundational research to real-world impact. We are delighted to be a founding partner in this ambitious initiative, which reflects a shared commitment to attracting exceptional talent and reinforcing the UK’s position as a home for world-class AI. We are especially proud that these scholarships are named after Karen Spärck Jones, a brilliant Cambridge computer scientist.”
A long-time valued member of the Cambridge community, Professor Spärck Jones was an undergraduate at Girton College (1953-1956), a Research Fellow at Newnham College (1965-1968), an Official Fellow of Darwin College (1968-1980) and a Fellow of Wolfson College (2000-2007).
She began her research career at the Cambridge Language Research Unit in the late 1950s and later taught for the MPhil in Computer Speech and Language Processing, on language systems, and for the Computer Science Tripos on information retrieval. She supervised many Cambridge PhD students across a wide range of topics and was a tireless advocate for women in computing, famously declaring: “I think it's very important to get more women into computing. My slogan is: Computing is too important to be left to men.”
Her international influence was recognised by numerous awards, including the ACM SIGIR Salton Award, the BCS Lovelace Medal, and election as a Fellow of the British Academy (of which she was also Vice-President from 2000 to 2002) and the American Association for Artificial Intelligence.
The University of Cambridge is delighted to honour her legacy by co-founding this exciting new programme, which was formally announced today at London Tech Week.
The Department for Science, Innovation and Technology (DSIT) has today announced the launch of the Spärck AI Scholarships, a major new initiative to nurture the next generation of AI leaders, with Cambridge University proud to join as a founding partner.
We are delighted to be a founding partner in this ambitious initiative, which reflects a shared commitment to attracting exceptional talent and reinforcing the UK’s position as a home for world-class AI.Professor Deborah Prentice, University of Cambridge Vice-Chancellor,University of CambridgeUniversity of Cambridge students walking into the Senate House for their graduation ceremony.
The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.
Cambridge and Manchester partnership to boost UK innovation and growth gets government backing
The Cambridge x Manchester Innovation Partnership – the first trans-UK innovation collaboration of its kind – will receive £4.8m of funding from Research England over three years, it has been announced. With further investment from the two universities, the total funding for the partnership will be £6m. The initiative aims to strengthen research networks, accelerate scale-up growth, drive private sector investment into R&D, and attract new foreign direct investment.
Led by the universities of Cambridge and Manchester, ‘CBG×MCR’ is supported by two mayoral combined authorities, city councils, key businesses (such as AZ, ARM, ROKU, and Microsoft), venture capitalists (Northern Gritstone and CIC), and angel investors (Cambridge and Manchester Angels).
As well as strengthening relations within and between the two cities, the partnership – fronted by Innovate Cambridge and Unit M – will pilot new approaches for delivering inclusive growth, providing insights to other cities, the wider higher education sector community, and local and national governments in the UK and internationally.
In the UK, collaboration has traditionally been focused on geographically proximate areas, such as Manchester-Liverpool, or Edinburgh-Glasgow. This new model of hyper-connected, place-to-place partnering – similar to those developed in the US’ Northeast Corridor, Coastal California, and China’s Greater Bay Area – combines complementary innovation capabilities to create globally competitive connected ecosystems.
Amplifying what each city can achieve independently, the model aims to drive national economic growth, responding directly to the UK government’s national industrial strategy.
Professor Deborah Prentice, Vice-Chancellor of the University of Cambridge, said: “This pioneering initiative brings together the combined strengths of Cambridge and Manchester to create something that is truly groundbreaking. By connecting our cities, we’re helping to build a more collaborative and dynamic environment in which innovative research can connect with industry, venture capital, and entrepreneurs, to drive economic growth and deliver real benefits for people and places across the UK.”
Professor Duncan Ivison, President and Vice-Chancellor at the University of Manchester, said: "Our partnership with Cambridge marks a new model of collaboration between UK universities. It brings together the distinctive strengths of each of our universities and cities, connecting two of the great innovation ecosystems to scale up what we can achieve. This new approach to innovation accelerates the time between discovery and impact, getting ideas into the real economy and our communities even more quickly to drive inclusive growth.”
Jessica Corner, Executive Chair of Research England, said: “This investment underscores our commitment to fostering innovation and collaboration across England. By connecting the vibrant ecosystems of Cambridge and Manchester, we aim to drive significant economic growth and create a model for place-based innovation that can be replicated nationwide."
Cambridge will join forces with Manchester as part of a pioneering collaboration to harness the combined strengths of both universities and cities – and boost innovation and growth for the whole of the UK
This pioneering initiative brings together the combined strengths of Cambridge and Manchester to create something that is truly groundbreaking.Professor Deborah Prentice, Vice-ChancellorDr Nik Johnson, former Mayor of Cambridgeshire and Peterborough; Prof Deborah Prentice, University of Cambridge; Prof Richard Jones, University of Manchester; and Andy Burnham, Mayor of Greater Manchester.
The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.
Whistleblowing tech based on Cambridge research launched by the Guardian
The Guardian has launched Secure Messaging as a module within its mobile news app to provide a secure and usable method of establishing initial contact between journalists and sources.
It builds on a technology - CoverDrop –developed by Cambridge researchers and includes a wide range of security features. The code is available online and is open source, to encourage adoption by other news organisations.
The app automatically generates regular decoy messages to the Guardian to create ‘air cover’ for genuine messages, even when they are passing through the cloud, preventing an adversary from finding out if any communication between a whistleblower and a journalist is taking place.
“This provides whistleblowers with plausible deniability,” said Professor Alastair Beresford from Cambridge’s Department of Computer Science and Technology.
“That’s important in a world of pervasive surveillance where it has become increasingly hazardous to be a whistleblower,” said Cambridge’s Dr Daniel Hugenroth, who co-led the development of CoverDrop with Beresford.
The technology also provides digital ‘dead drops’ – like virtual bins or park benches – where messages are left for journalists to retrieve. These are just two of a suite of functions that protect a source from discovery even if their smartphone is seized or stolen.
CoverDrop encrypts outgoing messages between the source and their named contact at the news organisation to ensure no other party can read their content. For this, it relies on cryptography using digital security key pairs consisting of a public and a secret key.
The source is given the public key that instructs the existing encryption technology on their smartphone to encrypt their messages to the Guardian. This key only works one way, so it can lock – but not unlock – their messages. The only person able to decode them is the whistleblower’s named contact at the Guardian, who uses their secret key to retrieve and decode the messages left in the dead drop.
CoverDrop also pads all messages to the same length, making it harder for adversaries – whether acting on their own behalf or for an organisation or state – to distinguish real messages from decoy ones.
The system fulfils a need long identified by media organisations: providing a highly secure, yet easy-to-use, system for potential sources who want to contact them with sensitive information.
“The Guardian is committed to public-interest journalism,” said Luke Hoyland, product manager for investigations and reporting at The Guardian. “Much of this is possible thanks to first-hand accounts from witnesses to wrongdoing. We believe whistleblowing is an important part of a functioning democracy and will always do our utmost to avoid putting sources at risk. So we're delighted to have worked with the University of Cambridge on turning their groundbreaking CoverDrop research into a reality.”
The research began with workshops with UK news organisations to find out how potential sources first contacted them. The researchers learned that whistleblowers often reach out to them via platforms that are either insecure or hard to use.
Beresford said that when they started looking for a practical solution to this problem, “we realised that news organisations already run a widely available platform from which they can offer a secure, usable method of initial contact – their mobile news app.”
“When sources send messages, their confidentiality and integrity can be assured through the secure messaging protocols on their smartphone,” said Hugenroth. “CoverDrop goes one step further and also protects the communication patterns between sources and journalists by using decoy messages to provide cover and padding all messages to the same length.”
Importantly, the researchers say, users of the new CoverDrop system won’t need to install any specialist software that chews up large amounts of battery power or slows down their phones.
Its simple interface looks and works just like a typical messaging app. And there are no traces left on the device that the CoverDrop system has ever been used on that phone before.
“When you open the app,” said Beresford, “even if you’ve already set up an account on it, the CoverDrop feature will look as though you haven’t used it. Its home screen will only offer two prompts – ‘Get started’ or ‘Check your message vault’. This is because if it’s stolen, or a user is under duress, we don’t want your phone to reveal to anyone that you’ve already used it.”
The development of CoverDrop began in the years after the whistleblower Edward Snowden, a former US intelligence contractor, leaked classified documents revealing the existence of global surveillance programmes.
This showed, the researchers said, the mass surveillance infrastructure available to nation states, which has profound implications for those who wish to expose wrongdoing within companies, organisations, and government.
Work on CoverDrop was first unveiled at an international Symposium on Privacy-Enhancing Technologies in 2022 by the Cambridge researchers (who originally included the late Professor Ross Anderson, a leader in security engineering and privacy).
When they published their peer-reviewed paper on the research at the conference, it attracted interest from the Guardian which, in collaboration with the researchers, subsequently helped develop CoverDrop from an academic prototype into a fully usable technology.
“The free press fulfils an important function in a democracy,” said Beresford. “It can provide individuals with a mechanism through which they can hold powerful people and organisations to account. We’re delighted that the Guardian is the first media organisation to adopt CoverDrop and will use it to help protect their sources.”
“All the CoverDrop code will be available online and open source,” said Hugenroth. “This transparency is essential for security-critical software and allows others to audit and improve it. Open-sourcing the code also means that other news organisations, particularly those with expertise in investigative journalism, could also use it. We would be excited to see them do so.”
References:
Mansoor Ahmed-Rengers et al. ‘CoverDrop: Blowing the Whistle Through A News App.’ Paper presented at the Privacy Enhancing Technologies Symposium. 12 July 2022, Sydney, Australia. DOI: 10.2478/popets-2022-0035
A new technical report on CoverDrop, describing its architecture and explaining how it works, is available at: www.coverdrop.org/coverdrop_guardian_implementation_june_2025.pdf
Whistleblowers can contact journalists more securely thanks to a new confidential and anonymous messaging technology co-developed by University of Cambridge researchers and software engineers at the Guardian.
Nanzeeba Ibnat via Getty ImagesIllustration of a whistleblower in crowd
The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.
Cambridge researcher awarded the Shaw Prize in Astronomy
Efstathiou, Emeritus Professor of Astrophysics (1909) at Cambridge’s Institute of Astronomy, shares the prize with Professor John Richard Bond from the Canadian Institute for Theoretical Astrophysics and the University of Toronto.
They were recognised for their pioneering research in cosmology, in particular for their studies of fluctuations in the cosmic microwave background. Their predictions have been verified by an armada of ground-, balloon- and space-based instruments, leading to precise determinations of the age, geometry, and mass-energy content of the universe.
Cosmology has undergone a revolution in the past two decades, driven mainly by increasingly precise measurements of the angular power spectrum of fluctuations in the temperature and polarisation fields of the cosmic microwave background, a relic of the early universe, most notably by NASA’s Wilkinson Microwave Anisotropy Probe spacecraft (2001–2010) and the European Space Agency’s Planck spacecraft (2009–2013).
These fluctuations are small — the strength of the background radiation is the same in all directions to better than 0.01% and it is only slightly polarised — but they offer a glimpse of the universe when it was very young, a test of many aspects of fundamental physics, insights into the nature of dark matter and dark energy, and measurements of many fundamental cosmological parameters with accuracies unimaginable to cosmologists a few decades ago.
Although many researchers contributed to the development of the theoretical framework that governs the behaviour of the cosmic microwave background, Bond and Efstathiou emphasised the importance of the background as a cosmological probe and took the crucial step of making precise predictions for what can be learned from specific models of the history and the composition of the mass and energy in the universe.
Modern numerical codes used to interpret the experimental results are based almost entirely on the physics developed by Bond and Efstathiou. Their work exemplifies one of the rare cases in astrophysics where later experimental studies accurately confirmed unambiguous, powerful theoretical predictions.
The interpretation of these experiments through Bond and Efstathiou’s theoretical models shows that the spatial geometry of the observable universe is nearly flat, and yields the age of the universe with a precision of 0.15%, the rate of expansion of the universe with a precision of 0.5%, the fraction of the critical density arising from dark energy to better than 1%, and so on. The measurements also strongly constrain theories of the early universe that might have provided the initial “seed” for all the cosmic structure we see today, and the nature of the dark matter and dark energy that dominate the mass-energy content of the universe.
Both Bond and Efstathiou have worked closely with experimentalists to bring their predictions to the test: they have been heavily involved in the analysis of cosmic microwave background data arising from a wide variety of experiments of growing sophistication and accuracy.
George Efstathiou received his BA in Physics from the University of Oxford and PhD in Astronomy from Durham University. He has held postdoctoral fellowships at the University of California, Berkeley, USA and the University of Cambridge. He was Savilian Professor of Astrophysics at Oxford, where he served as Head of Astrophysics until 1994. He returned to Cambridge in 1997 as Professor of Astrophysics, where he also served as Director of the Institute of Astronomy and the first Director of the Kavli Institute for Cosmology. He received the 2022 Gold Medal of the Royal Astronomical Society. He is a Fellow of the Royal Society of London and the Royal Astronomical Society, UK. He is a Fellow of King’s College, Cambridge.
Originally published on the Shaw Prize website.
Professor George Efstathiou has been awarded the Shaw Prize in Astronomy, one of the biggest prizes in the field.
Shaw PrizeJohn Richard Bond (left) and George Efstathiou (right)
The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.
Cambridge celebrates historic Varsity Athletics competition and World Athletics recognition
First held in 1864, Varsity Athletics remains an enduring symbol of sporting excellence and tradition. This year’s event, hosted at Wilberforce Road Sports Ground in Cambridge, was made even more special by a prestigious recognition from World Athletics: the awarding of two Heritage Plaques to Cambridge University Athletic Club (CUAC) and the Varsity Match itself.
World Athletics Heritage PlaqueFounded in 1857, CUAC is one of the oldest athletics clubs in the world. It played a pivotal role in the development of modern athletics, contributing to the rules and formats that govern the sport today. "Cambridge University Athletic Club is among a small group of pioneering organisations that helped shape modern athletics," World Athletics noted in its announcement.
In honour of this distinguished history, World Athletics CEO and Cambridge alumnus Jon Ridgeon (Magdalene College) returned to his alma mater to present the plaques during the Varsity weekend.
Athletics Varsity 2025Living up to the historic occasion, fierce but friendly rivalry was on display, with Cambridge securing victories in:
- Men’s Blues
- Para Team
- Men's 2nds
- Women’s 2nds
In an interview with Varsity newspaper ahead of the Athletics Varsity, CUAC President Jess Poon reflected on the club’s evolution and the importance of the Varsity Matches. She highlighted the club’s embrace of inclusivity, particularly with the expansion of women's and para-athletics matches, and celebrated the sense of tradition and camaraderie that continues to define the event.
Athletics Varsity plaque givingThis milestone celebration aligns closely with the University’s priority to encourage participation in sport and physical activity at all levels. Sport plays a critical role in supporting mental wellbeing, fostering leadership and communication skills, and enhancing employability among students.
Across the University, activity priorities include:
- Club Support Programme: Aimed at helping sports clubs like CUAC deliver high-quality training and competition experiences, ensuring sustainability and growth.
- University of Cambridge Athlete Performance Programme (UCAPP): Providing specialist support for high-performing athletes, enabling them to excel both in their sport and academically.
- Active Students Initiative: Promoting sport and physical activity for all students, regardless of ability or experience level, through programmes like 'Give it a Go', designed to remove barriers and encourage lifelong engagement with physical activity.
Bhaskar Vira, Pro-Vice-Chancellor for Education and Chair of the Sports Committee, has expressed the University’s enthusiasm for supporting sport: "Involvement in physical activity and sports provides a much-needed release from the intense pressures that are associated with life at Cambridge. I firmly believe that these are inherently complementary pursuits, allowing participants to achieve a balance between their work commitments and their own personal wellbeing."
The 150th Men's, 50th Women's, and 2nd Para Athletics Varsity Matches not only celebrated a rich and trailblazing past but also pointed towards a vibrant future, powered by a University-wide commitment to excellence, inclusion, and wellbeing in sport.
As Cambridge looks to build on this legacy, the University invites alumni and supporters to help sustain and grow these opportunities - ensuring that generations of Cambridge students continue to benefit from the profound personal, academic, and societal advantages that sport and physical activity bring.
Find out more information on how to support sport at Cambridge.
Varsity Athletics team
The world’s oldest athletics competition — the annual contest between Cambridge and Oxford — reached a landmark celebration this year, commemorating 150 years of men's competition, 50 years of women's competition, and the second year of the para-athletics Varsity.
Museum of World Athletics / James Rhodes
The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.
‘AI scientist’ suggests combinations of widely available non-cancer drugs can kill cancer cells
The research team, led by the University of Cambridge, used the GPT-4 large language model (LLM) to identify hidden patterns buried in the mountains of scientific literature to identify potential new cancer drugs.
To test their approach, the researchers prompted GPT-4 to identify potential new drug combinations that could have a significant impact on a breast cancer cell line commonly used in medical research. They instructed it to avoid standard cancer drugs, identify drugs that would attack cancer cells while not harming healthy cells, and prioritise drugs that were affordable and approved by regulators.
The drug combinations suggested by GPT-4 were then tested by human scientists, both in combination and individually, to measure their effectiveness against breast cancer cells.
In the first lab-based test, three of the 12 drug combinations suggested by GPT-4 worked better than current breast cancer drugs. The LLM then learned from these tests and suggested a further four combinations, three of which also showed promising results.
The results, reported in the Journal of the Royal Society Interface, represent the first instance of a closed-loop system where experimental results guided an LLM, and LLM outputs – interpreted by human scientists – guided further experiments. The researchers say that tools such as LLMs are not a replacement for scientists, but could instead be supervised AI researchers, with the ability to originate, adapt and accelerate discovery in areas like cancer research.
Often, LLMs such as GPT-4 return results that aren’t true, known as hallucinations. However, in scientific research, hallucinations can sometimes be beneficial if they lead to new ideas that are worth testing.
“Supervised LLMs offer a scalable, imaginative layer of scientific exploration, and can help us as human scientists explore new paths that we hadn’t thought of before,” said Professor Ross King from Cambridge’s Department of Chemical Engineering and Biotechnology, who led the research. “This can be useful in areas such as drug discovery, where there are many thousands of compounds to search through.”
Based on the prompts provided by the human scientists, GPT-4 selected drugs based on the interplay between biological reasoning and hidden patterns in the scientific literature.
“This is not automation replacing scientists, but a new kind of collaboration,” said co-author Dr Hector Zenil from King’s College London. “Guided by expert prompts and experimental feedback, the AI functioned like a tireless research partner—rapidly navigating an immense hypothesis space and proposing ideas that would take humans alone far longer to reach.”
The hallucinations – normally viewed as flaws – became a feature, generating unconventional combinations worth testing and validating in the lab. The human scientists inspected the mechanistic reasons the LLM found to suggest these combinations in the first place, feeding the system back and forth in multiple iterations.
By exploring subtle synergies and overlooked pathways, GPT-4 helped identify six promising drug pairs, all tested through lab experiments. Among the combinations, simvastatin (commonly used to lower cholesterol) and disulfiram (used in alcohol dependence) stood out against breast cancer cells. Some of these combinations show potential for further research in therapeutic repurposing.
These drugs, while not traditionally associated with cancer care, could be potential cancer treatments, although they would first have to go through extensive clinical trials.
“This study demonstrates how AI can be woven directly into the iterative loop of scientific discovery, enabling adaptive, data-informed hypothesis generation and validation in real time,” said Zenil.
“The capacity of supervised LLMs to propose hypotheses across disciplines, incorporate prior results, and collaborate across iterations marks a new frontier in scientific research,” said King. “An AI scientist is no longer a metaphor without experimental validation: it can now be a collaborator in the scientific process.”
The research was supported in part by the Alice Wallenberg Foundation and the UK Engineering and Physical Sciences Research Council (EPSRC).
Find out more about how Cambridge is changing the story of cancer.Reference:
Abbi Abdel-Rehim et al. ‘Scientific Hypothesis Generation by Large Language Models: Laboratory Validation in Breast Cancer Treatment.’ Journal of the Royal Society Interface (2025). DOI: 10.1098/rsif.2024.0674
An ‘AI scientist’, working in collaboration with human scientists, has found that combinations of cheap and safe drugs – used to treat conditions such as high cholesterol and alcohol dependence – could also be effective at treating cancer, a promising new approach to drug discovery.
STEVE GSCHMEISSNER/SCIENCE PHOTO LIBRARY via Getty ImagesScanning electron microscope image of breast cancer cells
The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.
Cambridge researchers awarded £7.5 million to build programmable plants
Imagine a plant with entirely new abilities – more nutritious food, crops that survive heatwaves, or leaves that grow useful materials. With new ARIA funding Cambridge researchers hope to unlock the technology to fast-track crop development and enhance plants with new qualities, like drought-tolerance to reduce the amount of water they need, or the ability to withstand pests and diseases.
Their research has the potential to revolutionise the future of agriculture and offer a radical new approach to securing food supply in the face of climate change.
Programmable plants – a major leap in plant biology“We’re building the tools to make plants programmable, just like software. This isn’t science fiction – it’s the future of agriculture,” said Professor Jake Harris, Head of the Chromatin and Memory group, and project lead for one of the ARIA-funded projects.
Harris’ team is awarded £6.5 million to build the world’s first artificial plant chromosome.
The ambitious aim of the Synthetic Plants programme is to develop artificial chromosomes and chloroplasts that can survive in a living plant. If the teams achieve this, it will be one the most significant advances in plant synthetic biology.
The international team involves collaborators from The University of Western Australia, biotech company Phytoform Labs and the Australian Genome Foundry at Macquarie University.
“Our idea is that instead of modifying an existing chromosome, we design it from the ground up,” Professor Harris said.
He added: “We’re rethinking what plants can do for us. This synthetic chromosome could one day help grow crops that are more productive, more resilient, and better for the planet.”
While synthetic chromosomes have been achieved in simpler organisms, such as bacteria and yeast, this will be the first attempt to create and deploy one entirely from scratch in a plant.
The project will use the moss Physcomitrium patens – a unique, highly engineerable plant – as a development platform to build and test a bottom-up synthetic chromosome, before transferring it into potato plants.
It also opens new possibilities for growing food and medicines in space, and for indoor agriculture. It could allow scientists to give elite crop varieties disease resistance, or to grow productively in new climates and environments.
Unlocking powerful applications in agricultureThe second funded project, led by Professor Alison Smith and Dr Paweł Mordaka in the Plant Metabolism group, aims to use the synthetic chloroplasts to enable plants to fix nitrogen, and produce vitamin B12. The use of fertilisers to supply nitrogen and promote good crop yields is the greatest cause of pollution from agriculture; reducing the need for these would promote more sustainable food production systems.
This builds on their previous work to design and build the entire chloroplast genome for the simple single-cell alga Chlamydomonas reinhardtii.
The Cambridge researchers are awarded almost £1 million, as part of a £9 million grant to this project. They are working with an international team of researchers from the UK, USA and Germany to transfer this technology to build synthetic chloroplasts in potato plants.
Professor Smith said: “Our success would unlock powerful applications in agriculture, like plants capable of nitrogen fixation or producing essential nutrients like vitamin B12, potentially reducing fertiliser dependence and addressing malnutrition. These traits have tremendous potential should they be engineered into plants.”
She added: “It will enable scientists to surpass what can be accomplished with gene editing and equip plants with new functions, from reducing agricultural water use to protecting crop yields in uncertain conditions.”
A unique opportunityThe ambitiousness of this project is outside the scope of most other UK funding schemes. Professor Harris believes this stems from ARIA’s unique approach to developing the research opportunity and goal along with the research community.
Harris said: “ARIA had a couple of events with synthetic biologists to look at what’s on the edge of possible, what could be useful as a moonshot approach that could really change things.”
He added: “It’s a totally different way of seeing things. We went from ‘here’s what we want to see in the world’ to ‘how are we going to get there?’ It catalysed a different team and a different way of thinking.”
“This work moves us beyond the limitations of natural genomes. It’s about designing entirely new capabilities in plants – from the molecular level up.”
Currently, it typically takes eight years to develop a new crop variety in the UK, but with this new technology it could be a matter of one year or even less. The speed of development would be dramatically increased, much in the way that revolutionary protein-folding technology like AlphaFold has massively accelerated the process of drug discovery.
Synthetic biology is already revolutionising the world of healthcare and could transform agriculture if applied to tailoring plant traits.
Two groups involving researchers from the University of Cambridge’s Department of Plant Sciences are among nine teams to have been awarded funding today from the UK’s Advanced Research + Invention Agency (ARIA)’s Synthetic Plants programme.
We’re building the tools to make plants programmable, just like software. This isn’t science fiction – it’s the future of agriculture.Jake Harrispkujiahe on GettyGloved hand holding plant in pot
The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.
Cambridge is the UK’s most innovation intensive city, says report
Dealroom’s Global Tech Ecosystem Index analyses and compares start-up ecosystems in 288 cities across 69 countries. To measure innovation intensity, it looks for ecosystems that are performing well relative to their population size. These hubs typically have high start-up activity, research intensity and strong links with local universities.
Diarmuid O’Brien, Pro-Vice-Chancellor for Innovation at the University of Cambridge, said: “It’s great to see that, as a relatively small city, Cambridge continues to lead the UK in innovation intensity but it’s no accident that we punch above our weight. In recent years, the University and the wider ecosystem have put in place a range of initiatives to ensure that we realise our potential and are able to bring transformative science and technologies out of the lab and into the real world.”
Gerard Grech, Head of Founders at the University of Cambridge, which supports new ventures emerging from the University, added: “Cambridge is proof of what happens when world-class research meets relentless ambition. While global venture capital funding in 2024 pulled back, Cambridge doubled investment - a powerful signal that deep tech innovation is increasingly leading the way in shaping our future economies.
“What makes Cambridge unique is its cutting-edge science, an increasing flywheel of people who have successfully scaled ventures, and a culture built to turn ground-breaking ideas into transformative companies.”
A new report by Dealroom shows that Cambridge is, for its size, the most innovative city in the UK. Globally, it ranks fourth behind US innovation powerhouses San Francisco, Boston and New York.
Hand holding test tubes in a lab
The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.
Cambridge researchers named as 2025 Academy of Medical Sciences Fellows
The new Fellows have been recognised for their remarkable contributions to advancing medical science, groundbreaking research discoveries and translating developments into benefits for patients and the wider public. Their work exemplifies the Academy’s mission to create an open and progressive research sector that improves health for everyone.
They join an esteemed Fellowship of 1,450 researchers who are at the heart of the Academy’s work, which includes nurturing the next generation of scientists and shaping research and health policy in the UK and worldwide.
One of Cambridge’s new Fellows, Professor Sam Behjati, is a former recipient of the Academy’s prestigious Foulkes Foundation medal, which recognises rising stars within biomedical research. Sam is Clinical Professor of Paediatric Oncology at the University and an Honorary Consultant Paediatric Oncologist at Addenbrooke’s Hospital, as well as Group Leader at the Wellcome Sanger Institute. His research is rooted in cancer genomics, phylogenetics, and single cell transcriptomics and spans a wide range of diseases and biological problems. More recently, his work has focused on the origin of cancers, in particular of childhood cancer. In addition, he explores how to use genomic data to improve the treatment of children. Sam is a Fellow at Corpus Christi College, Cambridge.
Also elected to the Academy of Medical Sciences Fellowship are:
Professor Clare Bryant, Departments of Medicine and Veterinary Medicine
Clare Bryant is Professor of Innate Immunity. She studies innate immune cell signalling during bacterial infection to answer fundamental questions about host-pathogen interactions and to search for new drugs to modify them. She also applies these approaches to study inflammatory signalling in chronic diseases of humans and animals. Clare has extensive collaborations with many pharmaceutical companies, is on the scientific advisory board of several biotech companies, and helped found the natural product company Polypharmakos. Clare is a Fellow of Queens’ College, Cambridge.
Professor Frank Reimann, Institute of Metabolic Science-Metabolic Research Laboratories
Frank Reimann is Professor of Endocrine Signaling. The main focus of his group, run in close partnership with Fiona Gribble, is the enteroendocrine system within the gut, which helps regulate digestion, metabolism, and how full we feel. Their work has included the use of animal models and human cellular models to understand how cells function. One of these cells, glucagon-like peptide-1 (GLP-1) is the target of therapies now widely used in the treatment of diabetes mellitus and obesity. How cells shape feeding behaviour has become a major focus of the lab in recent years.
Professor Mina Ryten, UK Dementia Research Institute
Mina Ryten is a clinical geneticist and neuroscientist, and Director of the UK Dementia Research Institute at Cambridge since January 2024. She also holds the Van Geest Professorship and leads a lab focused on understanding molecular mechanisms driving neurodegeneration. Mina’s research looks at how genetic variation influences neurological diseases, particularly Lewy body disorders. Her work has advanced the use of single cell and long-read RNA sequencing to map disease pathways and identify potential targets for new treatments. Her expertise in clinical care and functional genomics has enabled her to bridge the gap between patient experience and scientific discovery.
Professor Andrew Morris CBE FRSE PMedSci, President of the Academy of Medical Sciences, said: “The breadth of disciplines represented in this year’s cohort – from mental health and infectious disease to cancer biology and respiratory medicine – reflects the rich diversity of medical science today. Their election comes at a crucial time when scientific excellence and collaboration across disciplines are essential for addressing global health challenges both now and in the future. We look forward to working with them to advance biomedical research and create an environment where the best science can flourish for the benefit of people everywhere.”
The new Fellows will be formally admitted to the Academy at a ceremony on Wednesday 9 July 2025.
Four Cambridge biomedical and health researchers are among those announced today as newly-elected Fellows of the Academy of Medical Sciences.
Big T Images for Academy of Medical SciencesAcademy of Medical Sciences plaque
The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.
Enhanced breast cancer screening in the UK could detect an extra 3,500 cancers per year, trial shows
Around 10% of women have very dense breasts. Between the ages of 50 and 70, these women are up to four-times more likely to develop breast cancer compared to women with low breast density.
Over 2.2 million women receive breast screening in the UK each year. For women with very dense breasts, mammograms (breast X-rays), which are used for breast screening, can be less effective at detecting cancer. This is because denser breasts look whiter on mammograms, which makes it harder to spot small early-stage cancers which also appear white.
Published today in The Lancet, a trial of over 9000 women across the UK who have dense breasts and had a negative (no cancer) mammogram result, found 85 cancers.
The trial, called BRAID, tested different scanning methods that could be used in addition to mammograms to detect cancers in dense breasts. Per 1000 women screened, two of the methods detected 17-19 cancers that were not seen in mammograms.
The two methods are known as CEM (contrast enhanced mammography) and AB-MRI (abbreviated magnetic resonance imaging).
The researchers that ran the trial recommend that adding either of these methods to existing breast screening could detect 3,500 more cancers per year in the UK. Estimates suggest that screening reduces mortality for about 20% of cancers detected, so this could mean an extra 700 lives saved each year.
BRAID also included a third scanning method, ABUS (automated whole breast ultrasound), which also detected cancers not seen in mammograms but was three times less effective than CEM and AB-MRI.
Each of the three methods was used to scan around 2000 women. Per 1000 women scanned, CEM detected 19 cancers, AB-MRI found 17 cancers, and ABUS found 4.
Mammograms already detect approximately 8 cancers per 1000 women with dense breasts. This means additional scans could more than treble breast cancer detection in this group of women.
BRAID is the first trial to directly compare supplemental imaging methods and to demonstrate their value for early cancer detection as part of widespread screening. The team hope their results will be used to enhance screening programmes in the UK and globally to diagnose more cancers early.
More work is needed to confirm whether additional scans will reduce the number of deaths as cancers detected through screening are not always life-threatening.
The trial was led from Cambridge. It recruited across 10 UK sites, including over 2000 women at Addenbrooke’s Hospital, Cambridge.
The research was led by Professor Fiona Gilbert, Department of Radiology, University of Cambridge and honorary consultant radiologist at Addenbrooke’s Hospital, part of Cambridge University Hospitals NHS Foundation Trust (CUH). The trial was funded by Cancer Research UK with support from the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre (BRC).
Professor Gilbert said: “Getting a cancer diagnosis early makes a huge difference for patients in terms of their treatment and outlook. We need to change our national screening programme so we can make sure more cancers are diagnosed early, giving many more women a much better chance of survival.”
Professor Stephen Duffy, Emeritus Professor, Queen Mary University, London, trial statistician and screening programme expert said: “The NHS Breast Screening Programme has made a huge difference to many lives. Thanks to these results we can see that the technology exists to make screening even better, particularly for the 10% of women with dense breast tissue."
Dr David Crosby, head of prevention and early detection at Cancer Research UK, said: “Breast cancer screening is for people without symptoms and helps to spot the disease at an early stage, when treatment is more likely to be successful. But having dense breasts can make it harder to detect cancer.
“This study shows that making blood vessels more visible during mammograms could make it much easier for doctors to spot signs of cancer in women with dense breasts. More research is needed to fully understand the effectiveness of these techniques, but these results are encouraging.
“Remember, having dense breasts is not something you can check for yourself or change, but if you’re concerned at all, you can speak to your GP.”
Reference
Gilbert, FJ et al. Comparison of supplemental imaging techniques – interim results of BRAID (Breast Screening: risk adapted imaging for density) randomized controlled trial. Lancet; 22 May 2025; DOI: 10.1016/S0140-6736(25)00582-3
Press release from Cambridge University Hospitals NHS Foundation Trust
Researchers in Cambridge are calling for additional scans to be added to breast screening for women with very dense breasts. This follows a large-scale trial, which shows that extra scans could treble cancer detection for these women potentially saving up to 700 lives a year in the UK.
We need to change our national screening programme so we can make sure more cancers are diagnosed early, giving many more women a much better chance of survivalFiona GilbertTom Werner (Getty Images)Woman undergoing mammogram procedure - stock photoLouise’s storyLouise Duffield, age 60, a grandmother of four from Ely was diagnosed with early-stage breast cancer as a result of the BRAID trial.
Louise works in local government. She spends her free time knitting, and visiting 1940s events around the UK with her husband, Fred, and their two restored wartime Jeep. She is enthusiastic about clinical research and has previously participated as a healthy participant in several studies.
In 2023, Louise was invited to participate in the BRAID trial following her regular mammogram screening, which showed that she had very dense breasts. As part of the trial, Louise had an AB-MRI scan which identified a small lump deep inside one of her breasts.
“When they rang to say they’d found something, it was a big shock. You start thinking all sorts of things but, in the end, I just thought, at least if they’ve found something, they’ve found it early. The staff were brilliant, and so supportive.”
Soon after the MRI, Louise had a biopsy that confirmed she had stage 0 (very early) breast cancer within the ducts of one of her breasts. Six weeks later Louise underwent surgery to remove the tumour, during that time the tumour had already grown larger than it appeared on the scans.
“It’s been a stressful time and it’s a huge relief to have it gone. The team have been fantastic throughout. The tumour was deep in the breast so, if I hadn’t been on the trial, it could have gone unnoticed for years.
“I feel very lucky, it almost doesn’t feel like I’ve really had cancer. Without this research I could have had a very different experience.”
The location of Louise’s tumour meant it would have been difficult for her to find it through self-examination, and since it was not detected during her regular mammogram it would have been at least three years before she was invited for another.
Following a short course of radiotherapy, Louise is now cancer free. She will continue to be monitored for several years and will continue to be attending her regular mammograms every three years as part of the national breast cancer screening programme.
“This experience has highlighted to me how important screening is. If I hadn’t had the mammogram, I wouldn’t have been invited to the trial. Getting treated was so quick because they found the cancer early.”
The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.
Cambridge awarded silver-gilt medal at RHS Chelsea Flower Show debut
Presented by The Sainsbury Laboratory Cambridge University, the exhibit is part of a brand-new GreenSTEM section that celebrates cutting-edge research and innovation in the world of plant science.
Blooming Numbers takes visitors on an immersive journey through the latest discoveries in quantitative plant biology—starting with the humble flower and diving deep into molecular biology, genetics, imaging technologies, computational modelling, and the often-overlooked mathematical patterns that govern plant development.
“This award is just so exciting,” said Kathy Grube from the Sainsbury Laboratory.
“We came in in the morning to water the plants and turn on the microscopes, and the medal had been laid out by the judges. We were jumping up and down when we found it.”
The eye-catching exhibit was a collaborative effort across multiple Cambridge institutions and partners. The University’s Department of Engineering co-designed the infrastructure, drawing inspiration from the Fibonacci sequence—an iconic numerical pattern found throughout nature. The Pollinator Patch, a lush highlight of the exhibit, was designed and cultivated by Oakington Garden Centre to demonstrate pollinator-friendly planting. Darwin Nurseries added wildlife-friendly hanging baskets that captivated visitors and judges alike.
“One of our fellow exhibitors, who have been coming to Chelsea for years, told us that getting a silver-gilt on your first try is a real achievement,” said Kathy.
“The judges came over and said the design of the stand was fantastic, and they loved the interactive exhibits. We’re just so honoured.”
The RHS Chelsea Flower Show, the world’s most famous horticultural show, runs until the end of the week and attracts horticultural experts, designers, and plant lovers from across the globe.
The University of Cambridge has made a dazzling debut at the RHS Chelsea Flower Show, winning a prestigious silver-gilt medal for its interactive plant science exhibit, Blooming Numbers.
The Sainsbury Laboratory Cambridge University
The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.